Torben Straight Nissen

Torben Straight Nissen is an experienced biotech entrepreneur and has been a member of Flagship’s ecosystem since first joining as President of Rubius Therapeutics in 2016. He serves as a senior partner at Flagship Pioneering, contributing to Flagship’s strategic and operational objectives, including the origination and maturation of new Flagship Pioneering companies. Prior to joining Flagship, Torben was at Pfizer where he led Strategic Portfolio Management for the company’s worldwide R&D organization and oversaw the company’s portfolio, spanning all major therapeutic areas. He has held leadership positions in multiple biotech companies, including Ascendis Pharma and Maxygen. Torben currently serves on the board of Axcella Health and is the founding CEO of FL84.

Torben is a co-author or co-inventor of over 100 publications and published patents. He holds a PhD in molecular biology and biochemical engineering from the Technical University of Denmark and Carlsberg Laboratories and a Master of Science degree in chemical engineering from the Technical University of Denmark.